Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma

Journal of Neurosurgery

Volumn 123, Issue 4, 2015, Pages 989-997

  Sakai, Keiichi ^a,j   Shimodaira, Shigetaka ^b   Maejima, Shinya ^c   Udagawa, Nobuyuki ^c   Sano, Kenji ^b   Higuchi, Yumiko ^b   Koya, Terutsugu ^b   Ochiai, Takanaga ^d   Koide, Masanori ^e   Uehara, Shunsuke ^f   Nakamura, Midori ^f   Sugiyama, Haruo ^g   Yonemitsu, Yoshikazu ^h   Okamoto, Masato ⁱ   Hongo, Kazuhiro ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHINSHU UNIVERSITY HOSPITAL   (Japan)

^c Dendritic Cell Vaccination Therapy Center   (Japan)

^d Department of Oral Pathology ^*  (Japan)

^e Institute for Oral Science   (Japan)

^f MATSUMOTO DENTAL UNIVERSITY   (Japan)

^g OSAKA UNIVERSITY   (Japan)

^h KYUSHU UNIVERSITY   (Japan)

ⁱ KITASATO UNIVERSITY   (Japan)

^j Shinshu Ueda Medical Center   (Japan)

more..

Author keywords

Dendritic cell; Immunotherapy; Oncology; Relapsed malignant glioma; WT1

Indexed keywords

ANTINEOPLASTIC AGENT; DENDRITIC CELL VACCINE; INTERFERON; NIMUSTINE; PICIBANIL; PROCARBAZINE; RANIMUSTINE; STEROID; TEMOZOLOMIDE; TETRAMER; VINCRISTINE; WT1 PROTEIN; CANCER VACCINE;

ADULT; ARTICLE; ASTROCYTOMA; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CELL LYSATE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GENE TARGETING; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOGENICITY; INJECTION SITE; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEUROIMAGING; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SKIN MANIFESTATION; STEROID THERAPY; TISSUE SECTION; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR RECURRENCE; YOUNG ADULT; BRAIN NEOPLASMS; GLIOMA; IMMUNOTHERAPY; KIDNEY NEOPLASMS; PATHOLOGY; PROCEDURES; WILMS TUMOR;

ADULT; BRAIN NEOPLASMS; CANCER VACCINES; DENDRITIC CELLS; FEMALE; GLIOMA; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; WILMS TUMOR; YOUNG ADULT;

EID: 84953344525     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2015.1.JNS141554     Document Type: Article

References (48)

1. Adamson C, Kanu OO, Mehta AI, Di C, Lin N, Mattox AK, et al: Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin Investig Drugs 18:1061-1083, 2009
2. Ardon H, Van Gool S, Lopes IS, Maes W, Sciot R, Wilms G, et al: Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study. J Neurooncol 99:261-272, 2010
3. Ardon H, Van Gool SW, Verschuere T, Maes W, Fieuws S, Sciot R, et al: Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial. Cancer Immunol Immunother 61:2033-2044, 2012
4. Bregy A, Wong TM, Shah AH, Goldberg JM, Komotar RJ: Active immunotherapy using dendritic cells in the treatment of glioblastoma multiforme. Cancer Treat Rev 39:891-907, 2013
5. Chang CN, Huang YC, Yang DM, Kikuta K, Wei KJ, Kubota T, et al: A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma. J Clin Neurosci 18:1048-1054, 2011
6. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al: The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15:5323-5337, 2009
7. De Vleeschouwer S, Fieuws S, Rutkowski S, Van Calenbergh F, Van Loon J, Goffin J, et al: Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 14:3098-3104, 2008
8. Fadul CE, Fisher JL, Hampton TH, Lallana EC, Li Z, Gui J, et al: Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. J Immunother 34:382-389, 2011
9. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ: Dendritic cell immunotherapy: mapping the way. Nat Med 10:475-480, 2004
10. Fujiki F, Oka Y, Tsuboi A, Kawakami M, Kawakatsu M, Nakajima H, et al: Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB10405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes. J Immunother 30:282-293, 2007
11. Gu JH, Li G: Dendritic cell-based immunotherapy for malignant glioma. Neurosci Bull 24:39-44, 2008
12. Hashiba T, Izumoto S, Kagawa N, Suzuki T, Hashimoto N, Maruno M, et al: Expression of WT1 protein and correlation with cellular proliferation in glial tumors. Neurol Med Chir (Tokyo) 47:165-170, 2007
13. Heimberger AB, Sun W, Hussain SF, Dey M, Crutcher L, Aldape K, et al: Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. Neuro Oncol 10:98-103, 2008
14. Hoos A: Evolution of end points for cancer immunotherapy trials. Ann Oncol 23 (Suppl 8):viii47-viii52, 2012
15. Izumoto S, Tsuboi A, Oka Y, Suzuki T, Hashiba T, Kagawa N, et al: Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg 108:963-971, 2008
16. Jie X, Hua L, Jiang W, Feng F, Feng G, Hua Z: Clinical application of a dendritic cell vaccine raised against heat-shocked glioblastoma. Cell Biochem Biophys 62:91-99, 2012
17. Keilholz U, Letsch A, Busse A, Asemissen AM, Bauer S, Blau IW, et al: A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 113:6541-6548, 2009
18. Kimura Y, Tsukada J, Tomoda T, Takahashi H, Imai K, Shimamura K, et al: Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma. Pancreas 41:195-205, 2012
19. Kobayashi M, Sakabe T, Abe H, Tanii M, Takahashi H, Chiba A, et al: Dendritic cell-based immunotherapy targeting synthesized peptides for advanced biliary tract cancer. J Gastrointest Surg 17:1609-1617, 2013
20. Kuwabara K, Nishishita T, Morishita M, Oyaizu N, Yamashita S, Kanematsu T, et al: Results of a phase I clinical study using dendritic cell vaccinations for thyroid cancer. Thyroid 17:53-58, 2007
21. Li Z, Oka Y, Tsuboi A, Masuda T, Tatsumi N, Kawakami M, et al: WT1(235), a ninemer peptide derived from Wilms' tumor gene product, is a candidate peptide for the vaccination of HLA-A0201-positive patients with hematopoietic malignancies. Int J Hematol 82:458-459, 2005
22. Melief CJ: Cancer immunotherapy by dendritic cells. Immunity 29:372-383, 2008
23. Morita S, Oka Y, Tsuboi A, Kawakami M, Maruno M, Izumoto S, et al: A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data. Jpn J Clin Oncol 36:231-236, 2006
24. Nagayama H, Sato K, Morishita M, Uchimaru K, Oyaizu N, Inazawa T, et al: Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2. Melanoma Res 13:521-530, 2003
25. Nakatsuka S, Oji Y, Horiuchi T, Kanda T, Kitagawa M, Takeuchi T, et al: Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol 19:804-814, 2006
26. Nishida S, Hosen N, Shirakata T, Kanato K, Yanagihara M, Nakatsuka S, et al: AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1. Blood 107:3303-3312, 2006
27. Oji Y, Suzuki T, Nakano Y, Maruno M, Nakatsuka S, Jomgeow T, et al: Overexpression of the Wilms' tumor gene W T1 in primary astrocytic tumors. Cancer Sci 95:822-827, 2004
28. Oka Y, Tsuboi A, Oji Y, Kawase I, Sugiyama H: WT1 peptide vaccine for the treatment of cancer. Curr Opin Immunol 20:211-220, 2008
29. Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H, et al: Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A 101:13885-13890, 2004
30. Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, et al: Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with alpha-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 29:330-336, 2011
31. Okamoto M, Furuichi S, Nishioka Y, Oshikawa T, Tano T, Ahmed SU, et al: Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation. Cancer Res 64:5461-5470, 2004
32. Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, Yong WH, et al: Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res 17:1603-1615, 2011
33. Saikali S, Avril T, Collet B, Hamlat A, Bansard JY, Drenou B, et al: Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy. J Neurooncol 81:139-148, 2007
34. Saito S, Yanagisawa R, Yoshikawa K, Higuchi Y, Koya T, Yoshizawa K, et al: Safety and tolerability of allogeneic dendritic cell vaccination with induction of Wilms tumor 1-specific T cells in a pediatric donor and pediatric patient with relapsed leukemia: a case report and review of the literature. Cytotherapy 17:330-335, 2015
35. Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Bigner DD: Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol 20:267-275, 2008
36. Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, et al: Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 28:4722-4729, 2010
37. Scheibenbogen C, Letsch A, Thiel E, Schmittel A, Mailaender V, Baerwolf S, et al: CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 100:2132-2137, 2002
38. Stewart LA: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359:1011-1018, 2002
39. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466, 2009
40. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005
41. Sugiyama H: Cancer immunotherapy targeting Wilms' tumor gene WT1 product. Expert Rev Vaccines 4:503-512, 2005
42. Sugiyama H: Wilms' tumor gene WT1: its oncogenic function and clinical application. Int J Hematol 73:177-187, 2001
43. Takahashi H, Okamoto M, Shimodaira S, Tsujitani S, Nagaya M, Ishidao T, et al: Impact of dendritic cell vaccines pulsed with Wilms' tumour-1 peptide antigen on the survival of patients with advanced non-small cell lung cancers. Eur J Cancer 49:852-859, 2013
44. Vauleon E, Avril T, Collet B, Mosser J, Quillien V: Overview of cellular immunotherapy for patients with glioblastoma. Clin Dev Immunol 2010:1-18, 2010
45. Wheeler CJ, Black KL, Liu G, Mazer M, Zhang XX, Pepkowitz S, et al: Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res 68:5955-5964, 2008
46. Yamanaka R: Dendritic-cell-and peptide-based vaccination strategies for glioma. Neurosurg Rev 32:265-273, 2009
47. Yamanaka R, Homma J, Yajima N, Tsuchiya N, Sano M, Kobayashi T, et al: Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res 11:4160-4167, 2005
48. Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ: Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 64:4973-4979, 2004